Tags

Type your tag names separated by a space and hit enter

Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
J Clin Oncol. 2004 Feb 15; 22(4):678-85.JC

Abstract

PURPOSE

Human kallikrein 13 (hK13; encoded by the KLK13 gene) is a secreted serine protease expressed in endocrine tissues, including the prostate, testis, breast, and ovary. We have previously reported steroid hormone regulation of the KLK13 gene and its clinical value as a marker of favorable prognosis in breast cancer at the mRNA level. We hypothesized that hK13 may represent a potential biomarker for ovarian carcinomas.

PATIENTS AND METHODS

Using a newly developed enzyme-linked immunosorbent assay (ELISA), hK13 levels were quantified in 131 ovarian tumor extracts and correlated with various clinicopathological variables and outcome (progression-free survival [PFS], overall survival [OS]), over a median follow-up period of 42 months.

RESULTS

hK13 concentration in ovarian tumor cytosols ranged from 0 to 18.4 ng/mg of total protein. An optimal cutoff value of 0.13 ng/mg (67(th) percentile) was selected, based on the ability of hK13 values to predict the PFS of the study population, to categorize tumors as hK13-positive or negative. Women with hK13-positive tumors most often had early stage (stage I/II) disease, no residual tumor after surgery and optimal debulking success (P <.05). Univariate and multivariate Cox regression analyses revealed that patients with hK13-positive tumors had a significantly longer PFS and OS than hK13-negative patients (P <.05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK13-positive tumors (P =.007 and P =.002, respectively).

CONCLUSION

These results indicate that hK13 is an independent marker of favorable prognosis in ovarian cancer.

Authors+Show Affiliations

Department of Biochemistry and Molecular Biology, University of Athens, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14966091

Citation

Scorilas, Andreas, et al. "Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: a New Favorable Prognostic Marker." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 22, no. 4, 2004, pp. 678-85.
Scorilas A, Borgoño CA, Harbeck N, et al. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J Clin Oncol. 2004;22(4):678-85.
Scorilas, A., Borgoño, C. A., Harbeck, N., Dorn, J., Schmalfeldt, B., Schmitt, M., & Diamandis, E. P. (2004). Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 22(4), 678-85.
Scorilas A, et al. Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: a New Favorable Prognostic Marker. J Clin Oncol. 2004 Feb 15;22(4):678-85. PubMed PMID: 14966091.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. AU - Scorilas,Andreas, AU - Borgoño,Carla A, AU - Harbeck,Nadia, AU - Dorn,Julia, AU - Schmalfeldt,Barbara, AU - Schmitt,Manfred, AU - Diamandis,Eleftherios P, PY - 2004/2/18/pubmed PY - 2004/3/3/medline PY - 2004/2/18/entrez SP - 678 EP - 85 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 22 IS - 4 N2 - PURPOSE: Human kallikrein 13 (hK13; encoded by the KLK13 gene) is a secreted serine protease expressed in endocrine tissues, including the prostate, testis, breast, and ovary. We have previously reported steroid hormone regulation of the KLK13 gene and its clinical value as a marker of favorable prognosis in breast cancer at the mRNA level. We hypothesized that hK13 may represent a potential biomarker for ovarian carcinomas. PATIENTS AND METHODS: Using a newly developed enzyme-linked immunosorbent assay (ELISA), hK13 levels were quantified in 131 ovarian tumor extracts and correlated with various clinicopathological variables and outcome (progression-free survival [PFS], overall survival [OS]), over a median follow-up period of 42 months. RESULTS: hK13 concentration in ovarian tumor cytosols ranged from 0 to 18.4 ng/mg of total protein. An optimal cutoff value of 0.13 ng/mg (67(th) percentile) was selected, based on the ability of hK13 values to predict the PFS of the study population, to categorize tumors as hK13-positive or negative. Women with hK13-positive tumors most often had early stage (stage I/II) disease, no residual tumor after surgery and optimal debulking success (P <.05). Univariate and multivariate Cox regression analyses revealed that patients with hK13-positive tumors had a significantly longer PFS and OS than hK13-negative patients (P <.05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK13-positive tumors (P =.007 and P =.002, respectively). CONCLUSION: These results indicate that hK13 is an independent marker of favorable prognosis in ovarian cancer. SN - 0732-183X UR - https://www.unboundmedicine.com/medline/citation/14966091/Human_kallikrein_13_protein_in_ovarian_cancer_cytosols:_a_new_favorable_prognostic_marker_ L2 - http://ascopubs.org/doi/full/10.1200/JCO.2004.05.144?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -